Psychiatry Advisor

Our goal is to support mental health professionals by providing them with in-depth and practical information on clinical practices and medications. This information is designed to align with both current trends and new developments in care, enabling clinicians to enhance the outcomes for their patients.

National

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#632681

United States

#381703

Health/Mental Health

#1169

Traffic sources

Monthly visitors

Articles

CBT for Insomnia in Neurodevelopmental Conditions Offers Inconsistent Results

1 week ago | psychiatryadvisor.com | Ron Goldberg

Cognitive behavioral therapy for insomnia (CBT-I) among individuals with neurodevelopmental conditions (NDC) lacks guidance and offers inconsistent results which are often not maintained at follow-up, according to a systematic review published in the Journal of Sleep Research.
Most US Jails Face Barriers Providing Medications for OUD

2 weeks ago | psychiatryadvisor.com | Jessica Nye

A study published in JAMA Network Open found that jails in the United States (US) that provide medications for opioid use disorder (OUD) face challenges in making all 3 types of medications for OUD (MOUD) available. To evaluate trends in MOUD availability in US jails, researchers from the University of Chicago sourced data from a cross-sectional survey of 1028 US jails conducted in 2023.
Personal Factors May Be Over-Credited in Resiliency

2 weeks ago | psychiatryadvisor.com | Jessica Nye

Personal and social factors were associated with reduced depression symptomology among young adults, though this may reflect research bias, according to a systematic review published in The Lancet Psychiatry. In order to prevent and manage depression among young and emerging adults, a comprehensive understanding of depression risk and resilience factors is needed.
Novel Dexmethylphenidate Formulation Improves Pediatric ADHD Symptoms

3 weeks ago | psychiatryadvisor.com | Jaymin Kang

Topline data were announced from a phase 3 trial evaluating CTx-1301 for the treatment of pediatric patients aged 6 to 17 years with attention deficit/hyperactivity disorder (ADHD). CTx-1301 is a novel proprietary formulation of , a stimulant that increases norepinephrine and dopamine activity in the brain.
Drug-Device Combo Therapy Under Review for Parkinson Disease

3 weeks ago | psychiatryadvisor.com | Diana Ernst

The Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for ND0612 for the treatment of motor fluctuations in patients with Parkinson disease. ND0612 is an investigational drug-device therapy that provides a 24-hour continuous subcutaneous infusion of levodopa/carbidopa solution.
Patients With Parkinson Disease Commonly Experience Anxiety-Related Limitations

3 weeks ago | psychiatryadvisor.com | Jessica Nye

Nearly half of patients with Parkinson disease (PD) who experience anxiety symptoms report anxiety-related activity limitations, which is associated with an increased likelihood of seeking treatment. These are the findings of a study presented at the 2025 American Academy of Neurology (AAN) annual meeting, held from April 5 to 9, 2025, in San Diego, California, and published in the journal Neurology.
Quetiapine Is More Effective Than Lithium for Depression Augmentation

3 weeks ago | psychiatryadvisor.com | Lisa M Kuhns

Compared to lithium, quetiapine was more clinically and cost-effective for long-term augmentation in treatment-resistant depression, with greater symptom improvement, lower health-care costs, and similar safety and discontinuation rates over 12 months, according to study results published in The Lancet.
Significant Age Difference in Intolerance of Uncertainty Throughout Adulthood

3 weeks ago | psychiatryadvisor.com | Ron Goldberg

Throughout adulthood, intolerance of uncertainty (IU) changes significantly, and there may be a direct correlation between IU and anxiety, according to a scoping review and meta-analysis study published in the Journal of Anxiety Disorders.
Sedation from Antipsychotics Peaks Early and Persists in One Quarter of Patients

3 weeks ago | psychiatryadvisor.com | Lisa M Kuhns

Sedation from antipsychotic treatment in schizophrenia is common, typically begins within the first few days of initiation, and resolves in half of patients within one week. However, in one-quarter of cases, persists beyond four weeks, according to study results published in The Lancet.
Access to Gender Affirming Care for Transgender Youth Has Positive Outcomes

3 weeks ago | psychiatryadvisor.com | Jessica Nye

Youth identifying as transgender and gender-expansive who have access to social and medical gender affirming care (GAC) generally had positive outcomes, according to study results presented at the American Psychiatric Association Annual Meeting, held virtually from May 17 to 21, 2025 in Los Angeles, California. Professional medication organizations recommend in evidence-based guidelines that transgender and gender-expansive youth should receive social and medical GAC.